Transgenic rabbits expressing mutant essential light chain do not develop hypertrophic cardiomyopathy - PubMed (original) (raw)

Transgenic rabbits expressing mutant essential light chain do not develop hypertrophic cardiomyopathy

Jeanne James et al. J Mol Cell Cardiol. 2002 Jul.

Abstract

Mutations in multiple sarcomeric proteins can cause familial hypertrophic cardiomyopathy. Although a M149V mutation in the myosin light chain is associated with the human disease, the data from transgenic (TG) mouse models are conflicting. When a human genomic fragment containing the M149V essential myosin light chain was used to generate TG mice, the phenotype was recapitulated. However, when the mouse cDNA containing the mutation was used to generate TG animals, no phenotype could be discerned. TG rabbits can be a valuable complement and extension to mouse-based TG models and we wished to determine whether expression of this mutation in the rabbit heart would result in the disease. The rabbit essential light chain cDNA was isolated, sequenced, the M149V mutation made and the cDNA placed into the beta-myosin heavy chain promoter, which efficiently drives cardiac expression in the rabbit ventricles. Multiple TG rabbit lines showing different levels of protein replacement were obtained. No discernible pattern of disease was apparent at the structural or functional levels at either the neonatal, juvenile or adult stages. We conclude that the M149V mutation is not causative for FHC when expressed in the rabbit within the context of the endogenous protein.

PubMed Disclaimer

Cited by

Hereditary heart disease: pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains.
Yadav S, Sitbon YH, Kazmierczak K, Szczesna-Cordary D. Yadav S, et al. Pflugers Arch. 2019 May;471(5):683-699. doi: 10.1007/s00424-019-02257-4. Epub 2019 Jan 31. Pflugers Arch. 2019. PMID: 30706179 Free PMC article. Review.
Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine.
Fan J, Kitajima S, Watanabe T, Xu J, Zhang J, Liu E, Chen YE. Fan J, et al. Pharmacol Ther. 2015 Feb;146:104-19. doi: 10.1016/j.pharmthera.2014.09.009. Epub 2014 Sep 30. Pharmacol Ther. 2015. PMID: 25277507 Free PMC article. Review.
Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model.
Weber C, Neacsu I, Krautz B, Schlegel P, Sauer S, Raake P, Ritterhoff J, Jungmann A, Remppis AB, Stangassinger M, Koch WJ, Katus HA, Müller OJ, Most P, Pleger ST. Weber C, et al. Gene Ther. 2014 Feb;21(2):131-8. doi: 10.1038/gt.2013.63. Epub 2013 Dec 5. Gene Ther. 2014. PMID: 24305416 Free PMC article.
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model.
Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, Schinkel S, Leuchs B, Ludwig J, Qiu G, Weber C, Raake P, Koch WJ, Katus HA, Müller OJ, Most P. Pleger ST, et al. Sci Transl Med. 2011 Jul 20;3(92):92ra64. doi: 10.1126/scitranslmed.3002097. Sci Transl Med. 2011. PMID: 21775667 Free PMC article.
In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament.
Harris SP, Lyons RG, Bezold KL. Harris SP, et al. Circ Res. 2011 Mar 18;108(6):751-64. doi: 10.1161/CIRCRESAHA.110.231670. Circ Res. 2011. PMID: 21415409 Free PMC article. Review.

Transgenic rabbits expressing mutant essential light chain do not develop hypertrophic cardiomyopathy - PubMed (original) (raw)